Driving reinvestment in R&D for antibiotics and advocating their responsible use

WP1B: Setting, communicating and revising public health priorities

LEADER
Academic: Yehuda Carmeli, Tel Aviv Sourasky Medical Center, Israel

PARTNERS
E. Tacconelli, P. Beryl, T. Vilken,P. Shamsrizi (Universitätsklinikum Tübingen, Germany), L. Temkin, M. Kazma Matalon, Y. Almagor, G. Levi (Tel Aviv Sourasky Medical Center, Israel)

The private partners in DRIVE-AB are: AstraZeneca AB, GlaxoSmithKline Research & Development, F. Hoffmann-La Roche Ltd, MSD, Astellas Pharma Europe LTD, Pfizer Limited and Sanofi-Aventis Research & Development

OBJECTIVES

  1. Develop dynamic, updatable mathematical prediction models of multidrug-resistant pathogen spread from first detection to established endemicity.
  2. Determine the clinical impact of emerging MDR pathogens and AMR and to generalize the impact across various settings.
  3. Expand the agent-based predictive mathematical model developed in Aim 1 to predict the impact of propagation of MDROs in order to estimate the need for new antibiotics.
  4. Engage with stakeholders to communicate the models’ results.

KEY MESSAGES

  1. This project aims to generate models that may predict the emergence and spread of resistance.
  2. Models that project the spread and impact of resistance could help policy makers and antibiotic developers better allocate resources and direct efforts.
  3. To create updatable models to predict antibiotic resistance and its impact, which will provide policy makers with the data required for decision making.

DOWNLOADS & RESOURCES

Publication: EpideMiology and control measures of outBreaks due to Antibiotic-Resistant organisms in EurOpe (EMBARGO): a systematic review protocol

For more detail about Package 1B progress, please see our past NEWSLETTERS.

To get involved as a stakeholder, see the group’s STAKEHOLDER ENGAGEMENT PAGE.